Surfing the MASH Tsunami

Send us Fan Mail Co-authors Ken Cusi and Stephen Harrison discuss how the multidisciplinary call to action regarding the coming NASH Epidemic came to be, while NASH kNOWledge President Anthony Villiotti, Global Liver Institute Director of Global Policy Andrew Scott and Roger Green share their unique personal perspectives and Louise Campbell comments separately. This conversation starts with Ken Cu...

Send us Fan Mail Roger Green and Louise Campbell discuss some of the key elements of the "Preparing for the NASH Epidemic - a Call to Action" paper itself along with the discussion during Surfing NASH Episode 41. Louise focuses on several of her professional passions and key beliefs: the importance of affiliated health professionals (Nurses, Dieticians, Nurse Practitioners, Physician Ass...

Send us Fan Mail Co-authors Ken Cusi and Stephen Harrison discuss the multidisciplinary call to action regarding the coming NASH Epidemic, how the first paper came to be and what lies behind it, while NASH kNOWledge President Anthony Villiotti, Global Liver Institute Director of Global Policy Andrew Scott and Roger Green share their unique personal perspectives on the need for diverse health profe...

Send us Fan Mail Jeff Lazarus and Roger Green discuss the ease of creating valuable metrics in a comprehensive care model, while our three practitioners -- Stephen Harrison, Jörn Schattenberg and Louise Campbell -- dive further into how they believe this model will improve care.  KEY POINT: Broadening the number and diversity of health care providers assigned to each individual patient will improv...

Send us Fan Mail Stephen Harrison and Louise Campbell discuss their reactions to the recent paper, "Defining Comprehensive Models of Care for NAFLD." Stephen takes the perspective of a practicing hepatologist, Louise takes the perspective of a hepatology nurse, and both come to this discussion as NASH leaders and advocates. The combination of practical patient treatment experience and pa...

Send us Fan Mail Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss how they developed the care models for their recent paper, "Defining Comprehensive Models of Care for NAFLD." The authors researched care models around the world to find the ones that work best, and then developed eight foundational recommendations for co-ordinated NAFLD care centers....

Send us Fan Mail Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss their recent paper, "Defining Comprehensive Models of Care for NAFLD." In this vitally important paper, the authors researched care models around the world to find the ones that work best, and then developed eight foundational recommendations for co-ordinated NAFLD care centers. Jeff...

Send us Fan Mail This week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are publishing the interviews in full. Third up, Jörn Schattenberg and Ian Rowe Louise Campbell and Roger Green interview two frequent podcast guests, Jörn Schattenberg and Ian Rowe. In addition to reminiscing about the podcast, Jörn discusses the...

Send us Fan Mail This week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are publishing the interviews in full. Second up: Stephen Harrison and Naim Alkhouri Louise Campbell and Roger Green interview SurfingNASH co-founder Stephen Harrison and Naim Alkhouri, who Roger describes in this conversation as an "idea fou...

Send us Fan Mail This week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are publishing the interviews in full. First up: Donna Cryer. Louise Campbell and Roger Green interview Global Liver Institute President and CEO Donna Cryer about her experiences as regular, guest and back-up MC for the Surfing the NASH Tsunami po...

Send us Fan Mail Seven of our favorite Surfers join together to celebrate 20,000 Buzzsprout downloads and our one-year anniversary of moving to Buzzsprout. Louise Campbell and Roger Green interview Stephen Harrison, Donna Cryer, Naim Alkhouri, Ian Rowe and Jörn Schattenberg to discuss what we have experienced during the first year of SurfingNASH. Each participant reminisces on how they came to the...

Send us Fan Mail Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials. The first two conversations in this series focus largely on p...

Send us Fan Mail Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials. In this conversation, the group discusses the importance of b...

Send us Fan Mail Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.  In this conversation, the group discusses why motivating div...

Send us Fan Mail Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials. The group shares a wealth of goals, actions and the occasiona...

Send us Fan Mail J örn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the challenges in communicating the importance of NASH to medical specialties other than hepatology and gastroenterology. It has been common for industry advocates and financial analysts to discuss the potenti...

Send us Fan Mail Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the unique challenges posed by the complexity of NASH and NAFLD and the current state of diagnostic testing. It has been common for industry advocates and financial analysts to discuss the potential for the NAS...

Send us Fan Mail Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. In this conversation, each panelist identifies one significant reason the NASH market will develop differently than statins did. It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD d...

Send us Fan Mail Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions they treat (NASH vs. hypercholest...

Send us Fan Mail Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around care pathways and treatment roles as NASH becomes recognized as a multidisciplinary health challenge. The conversation started with a discussion of the attention paid to multi-disciplina...

Send us Fan Mail Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around drug development. The conversation addressed the various ways that the challenges that the COVID-19 pandemic created for clinical trials in 2020 played out in the drug development presen...

Send us Fan Mail Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around diagnostics. The conversation covered several issues relating to use and interpretation of non-invasive testing. Two issues addressed use on NITs in diagnostics and, separately, drug dev...

Send us Fan Mail Key opinion leaders Quentin Anstee, Mazen Noureddin and Ian Rowe join Stephen, Louise and Roger to discuss the major lessons and dangling questions from #ILC2021. The group shares perspectives, insights and questions on four key topics: diagnostics (including both non-invasive technologies and AI/machine learning), drug development, patient populations and policy. Mixed in here yo...

Send us Fan Mail Donna Cryer, Vlad Ratziu, Michael Charlton and Mazen Noureddin join Roger Green in reviewing the final day of #ILC 2021. The conversation revolved around three themes: non-invasive tests as presented at the morning LITMUS session; two promising but incomplete drug trials for a new class of agents and a possible therapy for controlled cirrhotics, and the opportunities and challenge...

Send us Fan Mail Manal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challenging Day Three of #ILC2021. Most of the presentations the panel covered focused on medications, the core ideas and discussions spoke to changes in thinking. One theme that ran through the discussion was about multi-disciplinary care...and not on...